Your shopping cart is currently empty

XH-30 is a potent, selective, and orally active PKMYT1 inhibitor with an IC50 of 4.1 nM. It suppresses the proliferation of P53-mutated triple-negative breast cancer (TNBC) cells by inducing G2/M phase release, DNA damage, and apoptosis. In the MDA-MB-231 mouse model, XH-30 demonstrates antitumor activity and can be used in studies of P53-mutated TNBC.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | XH-30 is a potent, selective, and orally active PKMYT1 inhibitor with an IC50 of 4.1 nM. It suppresses the proliferation of P53-mutated triple-negative breast cancer (TNBC) cells by inducing G2/M phase release, DNA damage, and apoptosis. In the MDA-MB-231 mouse model, XH-30 demonstrates antitumor activity and can be used in studies of P53-mutated TNBC. |
| Targets&IC50 | PKMYT1:4.1 nM |
| Molecular Weight | 337.38 |
| Formula | C19H19N3O3 |
| Cas No. | 3077136-87-6 |
| Smiles | O=C(N)C=1C=C2N=C(OC2=C(C1N)C3=C(C=CC(O)=C3C)C)C4CC4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.